Next Article in Journal
Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient
Previous Article in Journal
Successful Treatment of Immune Reconstitution Inflammatory Syndrome-Related Hemophagocytic Syndrome in an HIV Patient with Primary Effusion Lymphoma
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia

Thanawat Rattanathammethee
Wasan Theerajangkhaphichai
Ekarat Rattarittamrong
Sasinee Hantrakool
Chatree Chai-Adisaksopha
Lalita Norasetthada
Adisak Tantiworawit
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 110 Intravaroros Road, A. Muang, Chiang Mai 50200, Thailand
Author to whom correspondence should be addressed.
Hematol. Rep. 2017, 9(1), 22-27;
Submission received: 9 January 2017 / Revised: 26 January 2017 / Accepted: 5 February 2017 / Published: 23 February 2017


The aim of the present paper is to evaluate the efficacy and safety of colchicine and dapsone combination therapy in cases of steroid-dependent, relapsed and refractory immune thrombocytopenia (ITP). This is a retrospective study of ITP patients who attended the Hematology Clinic at Chiang Mai University Hospital (Thailand) from 1 January 2008 to 30 September 2014. Medical records and clinical data were reviewed for efficacy and adverse effects. Sixty-four ITP patients received the combination therapy. The median age was 46 years and 70.3% were female. The majority (65.6%) were relapsed ITP patients. Median platelet count before starting treatment was 22.6 × 109/L. The response rate was 82.8%, with 75.0% of patients having a complete response. Median time to response was 8 weeks. The response rate was higher in relapsed patients (90.4%) compared to refractory (61.5%) and steroid-dependent patients (77.8%). Steroid treatment was discontinued in 30 patients (50%) following combination therapy. The most common side effect was hemolysis due to dapsone which was found in eight patients (12.5%). We can therefore conclude that combination therapy with colchicine and dapsone is an alternative second-line therapy option in relapsed ITP cases with acceptable side effects.
Keywords: relapsed immune thrombocytopenia; colchicine; dapsone relapsed immune thrombocytopenia; colchicine; dapsone

Share and Cite

MDPI and ACS Style

Rattanathammethee, T.; Theerajangkhaphichai, W.; Rattarittamrong, E.; Hantrakool, S.; Chai-Adisaksopha, C.; Norasetthada, L.; Tantiworawit, A. The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia. Hematol. Rep. 2017, 9, 22-27.

AMA Style

Rattanathammethee T, Theerajangkhaphichai W, Rattarittamrong E, Hantrakool S, Chai-Adisaksopha C, Norasetthada L, Tantiworawit A. The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia. Hematology Reports. 2017; 9(1):22-27.

Chicago/Turabian Style

Rattanathammethee, Thanawat, Wasan Theerajangkhaphichai, Ekarat Rattarittamrong, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Lalita Norasetthada, and Adisak Tantiworawit. 2017. "The Efficacy of Colchicine and Dapsone Combination Therapy in Relapsed Immune Thrombocytopenia" Hematology Reports 9, no. 1: 22-27.

Article Metrics

Back to TopTop